Entrada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 07, 2023 at 07:20 am EST
Entrada Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net income was USD 35.46 million compared to net loss of USD 25.14 million a year ago. Basic earnings per share from continuing operations was USD 1.07 compared to basic loss per share from continuing operations of USD 0.8 a year ago. Diluted earnings per share from continuing operations was USD 1.02 compared to diluted loss per share from continuing operations of USD 0.8 a year ago.
For the nine months, net income was USD 2.86 million compared to net loss of USD 69.99 million a year ago. Basic earnings per share from continuing operations was USD 0.09 compared to basic loss per share from continuing operations of USD 2.24 a year ago. Diluted earnings per share from continuing operations was USD 0.08 compared to diluted loss per share from continuing operations of USD 2.24 a year ago.